NTHI - Public offerings

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- These companies are stepping into the market spotlight with very different catalysts: NeOnc (NASDAQ:NTHI) is drawing Wall Street attention around its brain-cancer pipeline and a $20 price target; Profusa (NASDAQ:PFSA) is advancing the regulatory path for its Lumee Oxygen Platform; Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) is expanding into blockchain-powered ecosystem finance through its MindWave Innovations subsidiary; and Greenland Energy Company (NASDAQ:GLND) has extended the timeline for its Jameson Land exploration program in East Greenland. NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Can

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline. Roth Capital analyst Jonathan Aschoff initiated coverage, according to a report published September 24. The timing is notable. NeOnc is no longer simply pitching an early-stage concept: the company has recently reported clinical data, raised fresh capital and is positioning its lead programs for potentially pivotal development. The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, saying the study produ

DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The small-cap market is delivering a mix of catalysts, with the following companies in particular putting substantial new developments in front of investors: Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), and Turbo Energy (NASDAQ:TURB). Aethlon Medical: Radical Reset Puts NOR-101 in the Spotlight Aethlon Medical (NASDAQ:AEMD) is attempting one of the most dramatic strategic resets in this group, announcing a definitive all-stock merger with privately held North Immunology alongside an oversubscribed private placement expected to generate approximately $180 million. If completed,

DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies (NASDAQ:NTHI) just removed a potentially significant overhang from its capital structure, redeeming all 6,000 outstanding shares of Series A Convertible Preferred Stock for $6 million in cash, with zero common shares issued in the process. The move comes only days after NeOnc announced a $15 million registered direct offering, creating a notable one-two punch: fresh capital for the clinical-stage biotech while simultaneously eliminating a preferred security that could have converted into common stock at a substantial discount. The company said the financing was specifically structured to support the redem

CALABASAS, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has redeemed for cash all 6,000 outstanding shares of its Series A Convertible Preferred Stock (the "Series A Preferred Stock") at their aggregate stated value of $6.0 million. Following the redemption, no shares of Series A Preferred Stock remain outstanding. The redemption was funded with a portion of the net proceeds from the Company’s $15 million registered direct offering announced on September 9, 2026, consi

DENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) executives put even more personal capital behind the company, following positive Phase 2a results for its experimental brain-cancer therapy NEO100. The latest purchase brings the total open-market buying by two senior executives to approximately $629,000 since the company announced its Phase 2a results on August 12. CEO, President and Executive Chairman Amir F. Heshmatpour purchased another 35,000 shares on September 15 for approximately $115,400, at a weighted average price of roughly $3.30 per share. That pushes his post-results purchases to 111,000 shares for approximately $418,

CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F. Heshmatpour purchased an additional 35,000 shares of NeOnc common stock in the open market on September 15, 2026, for approximately $115,400, at a weighted average price of approximately $3.30 per share, as will be reported in a Form 4 filed with the U.S. Securities and Exchange Commission (SEC). The purchase follows the Company's $15 million registere

DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is sending investors a signal that is impossible to ignore. The company's CEO, President and director, Amir F. Heshmatpour, just bought another 37,000 shares of NTHI at $3.6654 apiece, putting approximately $136,000 of his own money behind the stock and the timing is what makes this purchase particularly intriguing. NeOnc had just announced a $15 million registered direct offering at $4.20 per share, meaning Heshmatpour's latest purchase occurred at a substantial discount to the financing price. That is not the kind of insider transaction small-cap biotech traders casually dismiss

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: even a fundamentally strong company can get caught in the crossfire when a major drugmaker suffers a pipeline setback. Yesterday, a setback at Novartis (NYSE:NVS) sent ripples across the biotech space, pressuring companies whose own clinical and corporate announcements remained decidedly positive. The resulting selloff highlighted just how quickly investors can shift from company-specific fundamentals to broader sector risk. For smaller biotech names, that indiscriminate pressure can be painful, but it can also create potentially compelling rebound setups when posit

DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity. NeOnc Raises $15

DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging Phase 2a data and a string of open-market insider purchases. The company announced a $15 million registered direct offering priced at-the-market under Nasdaq rules, involving new and existing healthcare-focused institutional investors. The deal includes 3.57 million shares, or pre-funded warrants in lieu of shares, plus warrants covering another 3.57 million shares at a $4.20 exercise price. Closing is expected tomorrow, subject to customary conditions. The financing structure itself deserves

CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into definitive securities purchase agreements with new and existing healthcare focused institutional investors for the purchase and sale of 3,571,430 shares of the Company’s common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase up to 3,571,430 shares of the Company’s common stock at a combined purchase price of $4.20 per share (or